Claudia Lebedinsky

2.0k total citations · 1 hit paper
54 papers, 1.5k citations indexed

About

Claudia Lebedinsky is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Claudia Lebedinsky has authored 54 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 14 papers in Genetics. Recurrent topics in Claudia Lebedinsky's work include Sarcoma Diagnosis and Treatment (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers) and Ovarian cancer diagnosis and treatment (10 papers). Claudia Lebedinsky is often cited by papers focused on Sarcoma Diagnosis and Treatment (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers) and Ovarian cancer diagnosis and treatment (10 papers). Claudia Lebedinsky collaborates with scholars based in United States, Spain and France. Claudia Lebedinsky's co-authors include Andrés Poveda, Bradley J. Monk, Jean‐Yves Blay, Yusri Elsayed, Margaret von Mehren, Brian L. Samuels, Trilok Parekh, Stanley B. Kaye, Axel Le Cesne and Youn C. Park and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Claudia Lebedinsky

52 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

2009 397 citations Sant P. Chawla, Margaret von Mehren et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claudia Lebedinsky United States	15	732	693	517	286	259	54	1.5k
Andrew Dean Australia	17	1.1k 1.5×	694 1.0×	272 0.5×	267 0.9×	262 1.0×	104	1.6k
А. Н. Махсон Russia	15	1.2k 1.7×	563 0.8×	214 0.4×	397 1.4×	310 1.2×	23	1.7k
D. Fennelly Ireland	25	1.8k 2.4×	564 0.8×	265 0.5×	377 1.3×	417 1.6×	85	2.6k
César Serrano Spain	24	459 0.6×	1.3k 1.8×	124 0.2×	156 0.5×	226 0.9×	103	2.1k
R. Largillier France	14	940 1.3×	334 0.5×	226 0.4×	527 1.8×	162 0.6×	47	1.5k
L. Kayitalire France	17	745 1.0×	453 0.7×	158 0.3×	160 0.6×	163 0.6×	40	1.1k
Agnès Neuville France	27	704 1.0×	1.2k 1.8×	94 0.2×	269 0.9×	429 1.7×	56	2.0k
Philippe Follana France	20	1.1k 1.5×	523 0.8×	1.3k 2.5×	248 0.9×	333 1.3×	83	2.3k
Sreenivasa Nattam United States	20	1.9k 2.5×	1.0k 1.5×	418 0.8×	378 1.3×	760 2.9×	42	2.6k
Vera Gorbounova Russia	13	2.2k 3.0×	1.8k 2.7×	282 0.5×	354 1.2×	617 2.4×	23	3.2k

Countries citing papers authored by Claudia Lebedinsky

Since Specialization

Citations

This map shows the geographic impact of Claudia Lebedinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Lebedinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Lebedinsky more than expected).

Fields of papers citing papers by Claudia Lebedinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudia Lebedinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Lebedinsky. The network helps show where Claudia Lebedinsky may publish in the future.

Co-authorship network of co-authors of Claudia Lebedinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Lebedinsky. A scholar is included among the top collaborators of Claudia Lebedinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Lebedinsky. Claudia Lebedinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldlust, Samuel, Jong Hee Chang, Yoshitaka Narita, et al.. (2023). Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).. Journal of Clinical Oncology. 41(16_suppl). 2022–2022. 1 indexed citations

Taplin, Mary‐Ellen, Arif Hussain, Satish Shah, et al.. (2019). ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). TPS335–TPS335. 12 indexed citations

Harb, Wael A., Jeremy S. Abramson, Matthew A. Lunning, et al.. (2018). A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas. Annals of Oncology. 29. iii7–iii7. 24 indexed citations

Schore, Reuven J., Meenakshi Devidas, Archie Bleyer, et al.. (2016). Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. Blood. 128(22). 3965–3965. 4 indexed citations

Piha‐Paul, Sarina A., James A. Knost, Petros Nikolinakos, et al.. (2015). Colorectal cancer (CRC) cohort analysis of patients treated with buparlisib in a distinctive tissue-agnostic trial model for molecularly preselected tumors.. Journal of Clinical Oncology. 33(3_suppl). 644–644. 1 indexed citations

Slosberg, Eric D., Susan Snodgrass, Claudia Lebedinsky, et al.. (2015). The Signature Program: Bringing the Protocol to the Patient. Clinical Pharmacology & Therapeutics. 98(2). 124–126. 23 indexed citations

Piha‐Paul, Sarina A., James A. Knost, Fadi S. Braiteh, et al.. (2015). Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.. Journal of Clinical Oncology. 33(15_suppl). 2516–2516. 3 indexed citations

Talpaz, Moshe, Catriona Jamieson, Nashat Gabrail, et al.. (2012). A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.. Blood. 120(21). 2837–2837. 14 indexed citations

Pardo, Beatriz, Ramón Salazar, Eva Ciruelos, et al.. (2011). Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function. Medical Oncology. 29(3). 2240–2250. 6 indexed citations

10.

Poveda, Andrés, Stanley B. Kaye, Robert McCormack, et al.. (2011). Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecologic Oncology. 122(3). 567–572. 137 indexed citations

11.

Herzog, Thomas J., Jan B. Vermorken, Éric Pujade-Lauraine, et al.. (2011). Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. Gynecologic Oncology. 122(2). 350–355. 23 indexed citations

12.

Poveda, Andrés, Ignace Vergote, Sergei Tjulandin, et al.. (2010). Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Annals of Oncology. 22(1). 39–48. 117 indexed citations

13.

Kaye, Stuart, Nicoletta Colombo, B.J. Monk, et al.. (2010). Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Annals of Oncology. 22(1). 49–58. 47 indexed citations

14.

Vidal, Laura, Clare Barlow, Beatriz Pardo, et al.. (2010). Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Investigational New Drugs. 30(2). 616–628. 14 indexed citations

15.

Roszak, A., Mariusz Bidziński, Tudor–Eliade Ciuleanu, et al.. (2009). Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Annals of Oncology. 20(11). 1794–1802. 56 indexed citations

16.

Demetri, George D., Jean‐Yves Blay, A. Yovine, et al.. (2009). 9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. European Journal of Cancer Supplements. 7(2). 590–591. 3 indexed citations

17.

Poveda, Andrés, Stuart Kaye, Robert McCormack, et al.. (2009). Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD. Journal of Clinical Oncology. 27(15_suppl). 5551–5551. 2 indexed citations

18.

Cesne, Axel Le, Julien Dômont, Angela Cioffi, et al.. (2009). Mapping the literature: Role of trabectedin as a new chemotherapyoption in advanced pretreated soft tissue sarcoma. Drugs of today. 45(6). 403–403. 12 indexed citations

19.

McMeekin, Scott, Josep M. del Campo, Nicoletta Colombo, et al.. (2007). Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies. Journal of Clinical Oncology. 25(18_suppl). 5579–5579. 14 indexed citations

20.

Lebedinsky, Claudia, et al.. (1999). Nail disorders in patients treated with weekly paclitaxel (P). European Journal of Cancer. 35. S379–S379. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact